Humedics Q3 Operating Profit 7.8 Billion KRW... 204% Increase YoY

Driving Growth Performance in the Aesthetic Business

[Asia Economy Reporter Lee Gwanju] Humedix announced on the 14th that its individual-based sales in the third quarter reached 31.9 billion KRW, a 39% increase compared to the same period last year. Operating profit was 7.8 billion KRW, and net profit was 6.2 billion KRW, growing by 204% and 180%, respectively.

The rise in Humedix's third-quarter performance is attributed to growth in the aesthetic business. Demand for aesthetics centered on fillers (Elavie Premier, Revolline) and botulinum toxin (Liztox) increased, and in particular, overseas filler exports significantly expanded due to new filler registrations and exports in the South American region in addition to existing filler exports to China. Additionally, increased sales of active pharmaceutical ingredients and increased orders for disposable eye drops drove the performance.

Furthermore, profitability improved due to increased sales of fillers and disposable eye drops, and overall cost ratio decreased due to improved operating rates, continuing the trend of rising operating profit.

Humedix plans to maintain a steady sales growth trend in the fourth quarter through aggressive sales and marketing activities. The launch of new products such as the high-elasticity hyaluronic acid filler 'Elavie Premier Soft' and the adhesive transparent wound dressing 'Kiriel,' as well as increased contract manufacturing organization (CMO) orders, are expected to support growth.

A Humedix official stated, "With strong performance recorded every quarter and continuous growth in operating results, we expect the upward trend to continue in the fourth quarter."

This content was produced with the assistance of AI translation services.